Form 4: TG Therapeutics CFO Sean Power Granted 90,000 Shares

TG Therapeutics' CFO, Sean A. Power, was granted 90,000 restricted common shares on January 8, 2026, as part of an equity compensation plan.

Summary

• Sean A. Power, Chief Financial Officer of TG Therapeutics, Inc. (TGTX), acquired 90,000 shares of Common Stock.
• The transaction occurred on January 8, 2026, at a price of $0 per share, indicating a grant of restricted stock.
• These 90,000 restricted shares will vest in four equal installments (22,500 shares each) on January 1, 2027, January 1, 2028, January 1, 2029, and January 1, 2030.
• Following this transaction, Sean A. Power beneficially owns a total of 798,111 shares of Common Stock, which includes other restricted shares vesting over various periods.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 7

Explanation: The grant of restricted shares to a key executive like the CFO is generally viewed positively as it aligns management's long-term interests with those of shareholders through equity ownership and vesting incentives, contributing to stable governance and motivation.

Positives

• The grant of restricted shares aligns the Chief Financial Officer's long-term interests with those of shareholders, incentivizing sustained company performance.
• The transaction was executed under a Rule 10b5-1(c) plan, demonstrating a pre-planned and transparent approach to insider equity transactions.

Future Outlook

The filing indicates a future vesting schedule for the granted restricted shares, with installments occurring annually from January 1, 2027, through January 1, 2030, which ties executive compensation to long-term performance.

Industry Context

The grant of restricted stock to a Chief Financial Officer is a standard practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to retain key talent and align management's financial interests with the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) or similar equity awards to executive officers is a widely adopted practice across the biotechnology and pharmaceutical industries, including companies comparable to TG Therapeutics, as a means of long-term incentive compensation.
• This practice is consistent with industry benchmarks for executive compensation structures, which typically include a significant equity component to align management interests with shareholder returns over multi-year vesting periods.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aligns the CFO's financial incentives with the long-term performance of the company, potentially leading to decisions that enhance shareholder value.
• Employees: May signal stability in executive leadership and a commitment to long-term growth, which can positively influence employee morale and retention.

Next Steps

• The restricted shares will vest in four equal annual installments, with the first vesting on January 1, 2027, and subsequent vestings on January 1, 2028, January 1, 2029, and January 1, 2030.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to the CFO, which is a standard component of executive compensation designed to align management incentives with long-term shareholder value. It does not provide new fundamental information that would warrant a change in investment recommendation, thus a 'hold' stance is maintained, reflecting the existing outlook on the company's fundamentals.

Keywords

TG Therapeutics, TGTX, Form 4, Insider Transaction, Restricted Stock, Equity Grant, CFO, Sean Power, Executive Compensation